Covista SVP Sells 4,526 Shares for $615,000
Key Points
The disposition of 4,526 shares on August 7, 2026, realized a total value of ~$615,000.
The transaction resulted in a 14% reduction in the insider's direct equity holdings.
Activity was conducted under a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
Beck retains a direct stake of 28,544 shares valued at $4 million as of the August 7, 2026 close.
Douglas G. Beck, Senior Vice President, General Counsel, Corporate Secretary, and Institutional Support Services, sold 4,526 shares of Covista Inc. (NYSE:CVSA) on Aug. 7, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 4,526 |
| Transaction value | $615,000 |
| Post-transaction shares (directly held) | 28,544 |
| Post-transaction value | $4.02 million |
Transaction value based on SEC Form 4 weighted average sale price ($135.81); post-transaction value based on August 07, 2026, market close ($140.98).
Key questions
- How does this sale align with the insider's total equity exposure?
Following this 14% reduction in direct holdings, Beck maintains 28,544 shares. Footnotes clarify that the shares sold exceeded the company’s stock ownership and holding requirements. - What was the mechanism for this transaction?
The trade was non-discretionary and executed in pre-scheduled increments under a Rule 10b5-1 plan established in late 2025. Company policy prohibits discretionary trades by the reporting person absent a hardship exception. - What is the company's current financial profile and scale?
Covista, a Chicago-based firm in the education and training services industry, reported trailing twelve-month (TTM) revenue of $1.95 billion and net income of $267 million. As of the Aug. 10, 2026, market close, its market capitalization stood at $4.4 billion. - What has been the performance context for CVSA shares?
As of the transaction date on Aug. 7, 2026, the stock had delivered a one-year total return of 18%. The execution price of $135.81 was 3.67% below the market close of $140.98 on the day of the sale.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-10) | $128.71 |
| Market Capitalization | $4.4 billion |
| Revenue (TTM) | $2.0 billion |
| Net Income (TTM) | $251.6 million |
Company Snapshot
- Covista Inc. operates three primary business segments—Chamberlain, Walden, and Medical and Veterinary—that collectively deliver degree and non-degree educational offerings across nursing, health professions, and online learning modalities, generating revenue through tuition and institutional partnerships.
- The company generates revenue through a diversified higher education model encompassing traditional nursing degree programs, comprehensive online learning platforms offering certificates through doctoral degrees, and specialized medical and veterinary education services.
- Covista serves working professionals and career-focused students seeking flexible, accessible higher-education pathways, with particular emphasis on healthcare and allied health professions, targeting both domestic and international student populations.
Covista Inc. is a leading provider of specialized higher education services with a market capitalization of $4.4 billion and TTM revenue of $1.9 billion, demonstrating strong operational scale within the education and training services sector.
The company's diversified portfolio across nursing, online learning, and medical education positions it to capture secular demand trends in healthcare workforce development and lifelong learning. With a net profit margin of approximately 12.6% on TTM results, Covista exhibits solid profitability while maintaining strategic investments in its core educational delivery platforms.
What this transaction means for investors
This sale shouldn’t concern investors, as it represented a small portion of the executive’s holdings in the company’s stock. Beck still holds a sizable stake worth approximately $4 million.
Moreover, it was completed under a Rule 10b5-1 plan. Insiders often use this to execute pre-planned sales to avoid appearing to act on material non-public information.
Importantly, the business is performing well. TTM revenue grew 9% year over year, while operating margins increased. Operating income grew 12% year over year.
The stock recently pulled back, but trades at a modest forward price-to-earnings multiple of 14x. This is despite analysts expecting earnings to grow at a mid-teens annualized rate over the next several years.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Covista. The Motley Fool has a disclosure policy.